Project Grant HT94252410676
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...
This $1,189,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to target stem-like CD8 T cells in immunotherapy against kidney cancer. The grant was awarded on September 1, 2023 to The University of Texas Southwestern Medical Center, an academic medical institution and component of the University of Texas System, to be completed by August 31, 2027. Through this funding, UT Southwestern will conduct research...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
This federal Project Grant award for $968,904.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the University of Texas Southwestern Medical Center (UT Southwestern) to target the DNA damage response as a potential treatment for clear cell renal cell carcinoma. The project will be conducted at UT Southwestern's facilities in Dallas, Texas over a 4-year period from July 1, 2024 to June 30, 2028. This...
This $834,798 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports PET imaging research of HIF 2A in renal cancer at The University of Texas Southwestern Medical Center in Dallas, Texas. The research project aims to develop new diagnostic and treatment approaches for kidney cancer, which is a key focus area for this Defense Department program. The award will fund basic, translational, and clinical research...
The federal Project Grant award in the amount of $1,312,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to The University of Texas Southwestern Medical Center in Dallas, TX to "DEFINE THE HUMORAL IMMUNITY IN KIDNEY CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS." The grant has a performance period from September 1, 2024 to August 31, 2028 and supports advanced biomedical research...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
This Project Grant award in the amount of $322,371.00 from the Defense Health Agency (DHA) was provided to Yale University on May 15, 2024 under the Military Medical Research and Development program (CFDA 12.420). The award supports the research project "OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITOR-BASED THERAPIES FOR RENAL CELL CARCINOMA" with a planned completion date of May 14, 2027. The goal of this grant is to advance scientific understanding and therapeutic approaches for...